Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-09T19:51:28.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Therapeutic drug monitoring in clinical practice of early career psychiatrists in Europe: EPA ECPC TDM study results

Published online by Cambridge University Press:  19 July 2023

G. Schoretsanitis
G. Schoretsanitis*
Affiliation:
Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zurich, Switzerland

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Abstract

Therapeutic Drug Monitoring (TDM), i.e. the measurement of blood levels of antipsychotics, is a well-established clinical routine tool in the treatment with antipsychotics including clozapine. Nevertheless, worldwide there are different utilisation cultures and trends with use of TDM varying from regular to very limited. In order to assess attitudes regarding the use and utility of therapeutic drug monitoring in psychiatry trainees and young psychiatrists, the EPA ECPC Task Force on Communication and Publications is performing an online survey consisting of 12 questions previously validated in a british context to gather data on TDM attitudes, practices, and clinical setting.

Apart from capturing early career psychiatrists’ current practices and perspectives regarding antipsychotic TDM the goal of this project is to identify predictive factors for future use of therapeutic drug monitoring (TDM). Here we present the preliminary results of our currently ongoing survey.

Disclosure of Interest

G. Schoretsanitis Consultant of: HLS Therapeutics and ThermoFisher

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S54
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.